dc.contributor.author |
Carlton, Lauren H |
|
dc.contributor.author |
Chen, Tiffany |
|
dc.contributor.author |
Whitcombe, Alana L |
|
dc.contributor.author |
McGregor, Reuben |
|
dc.contributor.author |
Scheurich, Greg |
|
dc.contributor.author |
Sheen, Campbell R |
|
dc.contributor.author |
Dickson, James M |
|
dc.contributor.author |
Bullen, Chris |
|
dc.contributor.author |
Chiang, Annie |
|
dc.contributor.author |
Exeter, Daniel J |
|
dc.contributor.author |
Paynter, Janine |
|
dc.contributor.author |
Baker, Michael G |
|
dc.contributor.author |
Charlewood, Richard |
|
dc.contributor.author |
Moreland, Nicole J |
|
dc.date.accessioned |
2021-11-08T22:54:51Z |
|
dc.date.available |
2021-11-08T22:54:51Z |
|
dc.date.issued |
2021-7-30 |
|
dc.identifier.citation |
Epidemiology and infection 149:e173 30 Jul 2021 |
|
dc.identifier.issn |
0950-2688 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/57310 |
|
dc.description.abstract |
<jats:title>Abstract</jats:title>
<jats:p>New Zealand has a strategy of eliminating SARS-CoV-2 that has resulted in a low incidence of reported coronavirus-19 disease (COVID-19). The aim of this study was to describe the spread of SARS-CoV-2 in New Zealand via a nationwide serosurvey of blood donors. Samples (<jats:italic>n</jats:italic> = 9806) were collected over a month-long period (3 December 2020–6 January 2021) from donors aged 16–88 years. The sample population was geographically spread, covering 16 of 20 district health board regions. A series of Spike-based immunoassays were utilised, and the serological testing algorithm was optimised for specificity given New Zealand is a low prevalence setting. Eighteen samples were seropositive for SARS-CoV-2 antibodies, six of which were retrospectively matched to previously confirmed COVID-19 cases. A further four were from donors that travelled to settings with a high risk of SARS-CoV-2 exposure, suggesting likely infection outside New Zealand. The remaining eight seropositive samples were from seven different district health regions for a true seroprevalence estimate, adjusted for test sensitivity and specificity, of 0.103% (95% confidence interval, 0.09–0.12%). The very low seroprevalence is consistent with limited undetected community transmission and provides robust, serological evidence to support New Zealand's successful elimination strategy for COVID-19.</jats:p> |
|
dc.language |
en |
|
dc.publisher |
Cambridge University Press (CUP) |
|
dc.relation.ispartofseries |
Epidemiology and Infection |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Public, Environmental & Occupational Health |
|
dc.subject |
Infectious Diseases |
|
dc.subject |
COVID-19 |
|
dc.subject |
elimination |
|
dc.subject |
New Zealand |
|
dc.subject |
receptor binding domain |
|
dc.subject |
SARS-CoV-2 |
|
dc.subject |
seroprevalence |
|
dc.subject |
serosurvey |
|
dc.subject |
Spike |
|
dc.subject |
SEROPREVALENCE |
|
dc.subject |
ANTIBODIES |
|
dc.subject |
1117 Public Health and Health Services |
|
dc.title |
Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1017/s0950268821001643 |
|
pubs.begin-page |
e173 |
|
pubs.volume |
149 |
|
dc.date.updated |
2021-10-21T22:37:46Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000681640400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e41486220adb198d0efde5a3b153e7d |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Article |
|
pubs.subtype |
Journal |
|
pubs.elements-id |
862439 |
|
dc.identifier.eissn |
1469-4409 |
|
pubs.number |
e173 |
|
pubs.online-publication-date |
2021-7-30 |
|